Treatment with E1231 in the MetS/E group results in significant reductions in SBP, FBG, fasting serum insulin, HOMA-IR, OGTT AUC, serum creatinine, and microalbumin (p < 0.0001 for all). Here, INS is linked to metabolic syndrome.